Armata Pharmaceuticals (ARMP) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Molecular Partners (MOLN) has outperformed Armata Pharmaceuticals (ARMP) over the past year, losing 37.5% versus a loss of 56.9%. Over five years, ARMP leads with a -42.0% price change compared with -77.9% for MOLN. Armata Pharmaceuticals is the larger company by market cap ($112.7 million vs $96.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | MOLN |
|---|---|---|
| Share price | $3.03 | $2.53 |
| Market cap | $112.69M | $96.80M |
| 1-day change | +1.68% | -5.25% |
| YTD return | -51.75% | -42.07% |
| 1-year return | -56.90% | -37.50% |
| 5-year return | -41.95% | -77.87% |
| EPS (TTM) | $-4.17 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-173.80M | — |
| 52-week high | $14.98 | $5.36 |
| 52-week low | $2.40 | $2.52 |
| Distance from 52-week high | -79.77% | -52.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +477.56% | +295.64% |
| Average volume | 182.52K | 1.63K |
| Shares outstanding | 37.19M | 38.34M |
| Employees | 61 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed ARMP by 19.4 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
ARMP vs MOLN FAQ
Which is bigger, Armata Pharmaceuticals or Molecular Partners?
Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $112.69M compared with $96.80M for Molecular Partners (MOLN).
Which stock has performed better over the past year, ARMP or MOLN?
MOLN returned -37.50% over the past 12 months, compared with -56.90% for ARMP (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.